Context Therapeutics Inc. files 2024 Proxy Statement

TL;DR

Context Therapeutics filed its proxy statement for the Sept 17 meeting. Get ready to vote.

AI Summary

Context Therapeutics Inc. filed a definitive proxy statement (DEF 14A) on July 24, 2024, for its annual meeting on September 17, 2024. The company, incorporated in Delaware, is in the pharmaceutical preparations industry and is headquartered in Philadelphia, PA. This filing outlines the agenda and proposals for the shareholder meeting.

Why It Matters

This filing provides shareholders with crucial information regarding the upcoming annual meeting, including proposals to be voted on, which can impact the company's future direction and governance.

Risk Assessment

Risk Level: low — This filing is a routine proxy statement for an annual shareholder meeting and does not contain new financial or operational risks.

Key Players & Entities

• Context Therapeutics Inc. (company) — Registrant
• 2001 Market Street, Suite 3915 Unit #15, Philadelphia, PA 19103 (address) — Business and Mail Address
• 267-225-7416 (phone_number) — Business Phone
• 20240917 (date) — Conformed Period of Report
• 20240724 (date) — Filing Date

FAQ

Key Financial Figures

• $0.001 — f the Company's common stock, par value $0.001 per share, from 100,000,000 to 200,000,

Filing Documents

• contexttherapeutics2024spe.htm (DEF 14A) — 150KB
• contexttherapeuticsinc_vxp.jpg (GRAPHIC) — 192KB
• contexttherapeuticsinc_vxpa.jpg (GRAPHIC) — 427KB
• download.jpg (GRAPHIC) — 12KB
• 0001842952-24-000055.txt ( ) — 1019KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 10 HOUSEHOLDING OF PROXY MATERIALS 11 OTHER MATTERS 12 APPENDIX A 13 Table of Contents CONTEXT THERAPEUTICS INC. 2001 Market Street, Suite 3915, Unit #15 Philadelphia, Pennsylvania 19103 PROXY STATEMENT FOR THE SPECIAL MEETING OF STOCKHOLDERS To Be Held On September 17, 2024 QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING We are providing you with these proxy materials because the Board of Directors of Context Therapeutics Inc. (the Board) is soliciting your proxy to vote at a Special Meeting of Stockholders (the Special Meeting) of Context Therapeutics Inc. (the Company), including at any adjournments or postponements thereof, to be held on Tuesday, September 17, 2024 at 830 a.m. Eastern Time. The Special Meeting will be a virtual stockholder meeting through which you can listen to the meeting and vote online. The Special Meeting can be accessed by visiting www.virtualshareholdermeeting.comCNTX2024SM and entering your 16-digit control number (included on the Notice of Internet Availability of Proxy Materials sent to you). You are invited to attend the Special Meeting to vote on the proposals described in this proxy statement. However, you do not need to attend the Special Meeting to vote your shares. Instead, you may simply follow the instructions below to submit your proxy. The proxy materials, including this proxy statement, are being distributed and made available on or about July 24, 2024. As used in this proxy statement, references to we, us, our, Context and the Company refer to Context Therapeutics Inc. and our consolidated subsidiaries. Why did I receive a Notice of Internet Availability of Proxy Materials on the Internet instead of a full set of proxy materials Pursuant to rules adopted by the Securities and Exchange Commission (the SEC), we have elected to provide access to our proxy materials over the Internet rather than printing and mailing the proxy mate

View Full Filing

View this DEF 14A filing on SEC EDGAR